Matinicus Pharma
Developer of a modified hemoglobin-based injectable oxygen carrier and a modular manufacturing platform for purified hemoglobin products. Focus areas include extraction and chemical stabilization of bovine-derived hemoglobin, large-scale purification and scale-up, preclinical evaluation in trauma/ischemia and organ perfusion, and regulatory pathways for veterinary and human use.
Industries
Nr. of Employees
small (1-50)
Matinicus Pharma
Malvern, Pennsylvania, United States
Products
Modified hemoglobin injectable oxygen carrier (m-HPAOC)
An injectable, chemically stabilized and polymerized hemoglobin solution derived from bovine blood designed to deliver dissolved oxygen to tissues and organs; formulated for room-temperature stability and universal compatibility with all blood types.
Modified hemoglobin injectable oxygen carrier (m-HPAOC)
An injectable, chemically stabilized and polymerized hemoglobin solution derived from bovine blood designed to deliver dissolved oxygen to tissues and organs; formulated for room-temperature stability and universal compatibility with all blood types.
Services
Licensing of modular manufacturing designs and provision of a documented digital operational package to support equivalent biological product manufacture across sites.
Licensing of modular manufacturing designs and provision of a documented digital operational package to support equivalent biological product manufacture across sites.
Expertise Areas
- Hemoglobin-based oxygen therapeutics
- Organ preservation and ex-vivo perfusion
- Preclinical models for trauma and ischemia
- Biologics purification and scale-up
Key Technologies
- High-performance liquid chromatography (HPLC) for purification
- Membrane filtration methods for large-scale purification
- Gel permeation chromatography for molecular-weight profiling
- Chemical crosslinking/polymerization of proteins
News & Updates
PDF compilation of publications related to hemoglobin-based oxygen carriers and preclinical/clinical studies provided on the site.
Bovine hemoglobin products previously approved for veterinary indications and used in approximately 300,000 treatment episodes across multiple species; veterinary approval initially obtained in 1998.
PDF compilation of publications related to hemoglobin-based oxygen carriers and preclinical/clinical studies provided on the site.
Bovine hemoglobin products previously approved for veterinary indications and used in approximately 300,000 treatment episodes across multiple species; veterinary approval initially obtained in 1998.